Aisling Capital Mergers and Acquisitions Summary

Private Equity Profile

In the last 3 years, Aisling Capital has acquired 1 company. It has also invested in 2 others.

Aisling Capital’s most common sectors for investment are life science (72%) and medical products (22%). The Firm’s most common investment types include venture (56%) and stake purchase (19%). In total, Aisling Capital has invested in 13 US states and 2 different countries. Its largest (disclosed) acquisition occurred in 2007 when it acquired Catalent for $3.3B.

In the last 3 years, Aisling Capital has exited 3 companies. The Firm’s most common exit type is trade sale (75%). Aisling Capital’s largest (disclosed) exit occurred in 2017 when it sold ZELTIQ Aesthetics for $2.5B.

Join Mergr to view Aisling Capital’s full profile and discover more large private equity firms just like it.

M&A Summary

  • M&A Total Activity69
    • M&A Buy Activity38
    • M&A Sell Activity31
  • Total Sectors Invested 4
  • Total Countries Invested 2
  • M&A Buy/Sell Connections 32
  • M&A Advisors 3

Aisling Capital

888 Seventh Avenue, 12th Floor,
New York, New York 10106
United States
(212) 651-6380
www.aislingcapital.com

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital

Geographic Preferences: East US, Midwest US, South US, West US, United Kingdom, Western Europe, Eastern Europe, Scandinavia

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size 20 50
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '15 '16 '17 '18 '19 '20 T
Buy (0.8/yr) # 34 1 2 1 - - 38
vol $6.5B $6.5B
Sell (0.6/yr) # 28 - 2 - - 1 31
vol $6.1B $2.5B $8.6B
  69

Most Recent M&A

Company Date Value Type
Aimmune Therapeutics, Inc. 2020-08-31 - Add-on Acquisition
Brisbane, California · www.aimmune.com
Aeglea BioTherapeutics, Inc. 2018-01-01 - Stake Purchase
Austin, Texas · www.aegleabio.com
Arcus Biosciences, Inc. 2017-11-13 - Stake Purchase
Hayward, California · www.arcusbio.com
Miramar Labs, Inc. 2017-06-12 20M USD Add-on Acquisition
Sunnyvale, California · www.miradry.com
ZELTIQ Aesthetics, Inc. 2017-02-13 2.5B USD Add-on Acquisition
Pleasanton, California · www.zeltiq.com
Ajax Health LLC 2017-01-01 - Buyout (LBO, MBO, MBI)
Menlo Park, California · www.ajaxhealth.com
Syros Pharmaceuticals, Inc. 2016-01-12 - Venture
Cambridge, Massachusetts · www.syros.com
Aimmune Therapeutics, Inc. 2015-01-01 - Stake Purchase
Brisbane, California · www.aimmune.com
Ambit Biosciences Corp. 2014-09-28 315M USD Add-on Acquisition
San Diego, California · www.ambitbio.com
Loxo Oncology, Inc. 2014-08-01 - IPO
Stamford, Connecticut · www.loxooncology.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 10 (67%) 115M (100%) 27 (71%) 6.5B (100%)
Medical Products 3 (20%) - 8 (21%) 24M (< 1%)
Consumer Products 1 (7%) - 2 (5%) -
Healthcare Services 1 (7%) - 1 (3%) -
Total 15 $115M 38 $6.5B

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 14 (93%) 115M (100%) 37 (97%) 6.5B (100%)
  California 3 (20%) - 10 (26%) -
  North Carolina 3 (20%) 37M (32%) 5 (13%) 3.0B (47%)
  New Jersey 1 (7%) - 5 (13%) 3.3B (51%)
  Massachusetts 2 (13%) 23M (20%) 4 (11%) 23M (< 1%)
  New York 1 (7%) 55M (48%) 3 (8%) 55M (1%)
  Florida - - 3 (8%) 69M (1%)
  Ohio 1 (7%) - 1 (3%) -
  Kentucky 1 (7%) - 1 (3%) -
  Texas 1 (7%) - 1 (3%) -
  Pennsylvania 1 (7%) - 1 (3%) -
  Connecticut - - 1 (3%) -
  Colorado - - 1 (3%) -
  Virginia - - 1 (3%) -
Switzerland 1 (7%) - 1 (3%) -
Domestic 14 (93%) 115M (100%) 37 (97%) 6.5B (100%)
Cross-border 1 (7%) - 1 (3%) -
Total 15 $115M 38 $6.5B

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture 8 (53%) 115M (100%) 21 (55%) 160M (2%)
Stake Purchase 4 (27%) - 7 (18%) -
Buyout (LBO, MBO, MBI) 2 (13%) - 6 (16%) -
Divestiture - - 1 (3%) 3.3B (51%)
Recapitalization - - 1 (3%) 3.0B (46%)
Growth Capital - - 1 (3%) 24M (< 1%)
PIPE 1 (7%) - 1 (3%) -
Total 15 $115M 38 $6.5B

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 12 (39%) 7.5B (87%)
Trade Sale 11 (35%) 1.1B (13%)
IPO 8 (26%) -
Total 31 $8.6B

Top M&A Advisors

Financial Deals
Stifel, Nicolaus & Co., Inc.
1
J.P. Morgan Securities LLC
1
Legal Deals
Morgan, Lewis & Bockius LLP
1

Deal Values

buy # Total
> $1B 2 $6.3B
< $100M 6 $184M
TOTAL $6.5B
Largest Catalent, Inc.
$3.3B (2007-01-25)
sell # Total
> $1B 3 $5.8B
$100M to $1B 8 $2.8B
< $100M 1 $20M
TOTAL $8.6B
Largest ZELTIQ Aesthetics, Inc.
$2.5B (2017-02-13)

M&A Connections

Deals %
Acquired from
PE Firm(s)
67%
2 67%
Strategic(s)
33%
1 33%
Exited to
Strategic(s)
100%
23 100%

 Subscribe to unlock this and 155,882
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.0K Private Equity Firms
  • 144K M&A Transactions
  • 152K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.1K M&A Advisors
    (Investment Banks and Law Firms)
  • 45K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.